期刊
NATURE MEDICINE
卷 26, 期 3, 页码 379-+出版社
NATURE PORTFOLIO
DOI: 10.1038/s41591-020-0755-1
关键词
-
资金
- European Research Council [311292]
- Swedish Research Council [2016-00906]
- Knut and Alice Wallenberg foundation [2017-0383]
- Marianne and Marcus Wallenberg foundation [2015.0125]
- Swedish Alzheimer Foundation [AF-745911, AF-843991, AF-846521]
- Swedish Brain Foundation [FO2019-0326, FO2019-0029]
- Swedish Medical Association [SLS-780901]
- Parkinson Foundation of Sweden [1127718]
- Skane University Hospital Foundation [2019-o000032]
- Swedish federal government under the ALF agreement [2018-Projekt0279]
- Medical Faculty at Lund University
- US National Institutes of Health [U24 NS072026, P30 AG19610]
- Arizona Department of Health Services [211002]
- Arizona Biomedical Research Commission [4001, 0011, 05-901, 1001]
- Michael J. Fox Foundation for Parkinson's Research
- GE Healthcare
- Region Skane (Wallenberg Molecular Medicine Fellow grant 2019)
- European Research Council (ERC) [311292] Funding Source: European Research Council (ERC)
Plasma phosphorylated tau181 (P-tau181) might be increased in Alzheimer's disease (AD), but its usefulness for differential diagnosis and prognosis is unclear. We studied plasma P-tau181 in three cohorts, with a total of 589 individuals, including cognitively unimpaired participants and patients with mild cognitive impairment (MCI), AD dementia and non-AD neurodegenerative diseases. Plasma P-tau181 was increased in preclinical AD and further increased at the MCI and dementia stages. It correlated with CSF P-tau181 and predicted positive Tau positron emission tomography (PET) scans (area under the curve (AUC) = 0.87-0.91 for different brain regions). Plasma P-tau181 differentiated AD dementia from non-AD neurodegenerative diseases with an accuracy similar to that of Tau PET and CSF P-tau181 (AUC = 0.94-0.98), and detected AD neuropathology in an autopsy-confirmed cohort. High plasma P-tau181 was associated with subsequent development of AD dementia in cognitively unimpaired and MCI subjects. In conclusion, plasma P-tau181 is a noninvasive diagnostic and prognostic biomarker of AD, which may be useful in clinical practice and trials. Plasma P-tau18 level increased with progression of Alzheimer's disease (AD) and differentiated AD dementia from other neurodegenerative diseases, supporting its further development as a blood-based biomarker for AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据